Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized open-label sublingual cannabidiol study in borderline personality disorder
MOH_2020-01-28_008586Phase 2Completed
- Sponsor
- BOL Pharma
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in borderline personality disorder (BPD) comparing CBD sublingual drops with CBD + THC sublingual drops (2 arms). Started Oct 2018; status: completed.
02
Drugs
cannabidioldronabinol
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on MOH_2020-01-28_008586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-28_008586.